MedTrace Logo

Efficacy of Propranolol Treatment to Prevent Melanoma Progression

NCT01988831 · Status: SUSPENDED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2019-05-10

No results posted yet for this study

Summary

Melanoma's incidence is increasing worldwide. The efforts made in melanoma screening led to an earlier detection of the primary tumour and a better prognosis, but melanoma remains an aggressive cancer when it comes to its metastatic stage. Three recent retrospective studies compared groups of patients diagnosed with primary melanoma and treated with betablockers for another indication to patients who never received betablockers. In these three studies, the outcome of the disease is significantly better for people under betablocker treatment with a decreased rate of recurrence and a better 5 years survival rate. Here we want to investigate the efficacy and the tolerability of an adjuvant treatment with propranolol for patients suffering from a primary melanoma with a high risk of recurrence.

Conditions

  • Stages III Skin Melanoma
  • Stages II Skin Melanoma
  • Stage IB Skin Melanoma

Interventions

DRUG

Propranolol hydrochloride

This intervention apply to Propranolol group

DRUG

Placebo pill

We use placebo pills alike propranolol commercial pills to ensure blindness of the subjects during the study.

Sponsors & Collaborators

  • University Hospital, Geneva

    lead OTHER

Principal Investigators

  • Frédérique-Anne Le Gal, MD/PhD · Hôpital cantonal universitaire de Genève

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-06-30
Primary Completion
2022-01-31
Completion
2022-03-31

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01988831 on ClinicalTrials.gov